David Quinn, MD
Medical Oncology · Los Angeles, CANPI 1043249584
Payments from drug & device makers
Across 673 payments — averaging $5887.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.8M
- Merck$1.3M
- Seagen Inc.$214K
- Pharmacyclics LLC, An Abbvie Company$183K
- Bayer$134K
- Puma Biotechnology, Inc.$116K
- plus $261K from 21 others
Across 5 payments — averaging $1014.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
- Astellas Pharma Global Development$853
- Pharmacyclics LLC, An Abbvie Company$238
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 155 | $1,789,399 |
| Merck | 272 | $1,265,177 |
| Seagen Inc. | 35 | $214,465 |
| Pharmacyclics LLC, An Abbvie Company | 32 | $182,914 |
| Bayer | 41 | $133,709 |
| Puma Biotechnology, Inc. | 17 | $115,655 |
| Astellas Pharma Global Development | 12 | $89,070 |
| Genentech, Inc. | 32 | $73,011 |
| Gilead(2 entities) | 15 | $23,795 |
| Clinigen, Inc. | 1 | $18,512 |
| Exelixis Inc. | 11 | $10,612 |
| AstraZeneca | 17 | $9,919 |
| E.r. Squibb & Sons, L.L.C. | 4 | $7,161 |
| GSK | 3 | $5,523 |
| Advanced Accelerator Applications | 4 | $4,046 |
| F. Hoffmann-la Roche AG | 2 | $3,375 |
| Bristol Myers Squibb | 2 | $3,110 |
| Immunomedics, Inc. | 2 | $2,856 |
| EMD Serono, Inc. | 1 | $2,500 |
| Johnson & Johnson | 5 | $2,415 |
| AVEO Pharmaceuticals, Inc. | 1 | $2,000 |
| Novartis | 1 | $1,540 |
| Astellas Pharma US Inc | 3 | $1,112 |
| Myovant Sciences Inc. | 1 | $101 |
| Genentech USA, Inc. | 2 | $76 |
| Edwards Lifesciences | 1 | $26 |
| Amgen | 1 | $22 |
How this compares
$3,962,101 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Los Angeles
- Sarmad SadeghiLos Angeles$26.1M
- Heinz-Josef LenzLos Angeles$11.6M
- Anthony El-KhoueiryLos Angeles$10.5M
- Stephen LiuLos Angeles$8M
- Mark AgulnikLos Angeles$5M
- Daphne StewartLos Angeles$4M
- Patricia YoungLos Angeles$3.1M
- David TranLos Angeles$3.1M
- Syma IqbalLos Angeles$1.9M
- Afsaneh BarziLos Angeles$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.